Original Article

The Expression and Diagnostic Value of LncRNA H19 in the Blood of Patients with Osteoarthritis


Background: To investigate the expression and diagnostic value of LncRNA H19 in the blood of patients with osteoarthritis.

Methods: A total of 130 cases of patients with osteoarthritis admitted to Jinling Hospital, Nanjing, China from Jun 2016 to Jul 2017 were elected as the study group, and 100 patients who underwent physical examination in Jinling Hospital during the same period were selected as the control group. The differences in expression levels of LncRNA H19 between the two groups were compared, the diagnostic value of LncRNA H19 in osteoarthritis and its relationship with clinical characteristics of patients with osteoarthritis were analyzed.

Results: The expression level of LncRNA H19 increased in peripheral blood of patients with osteoarthritis (P<0.05). The AUC, critical value, sensitivity and specificity of the diagnosis of osteoarthritis were 0.891, 1.879, 96.00% and 85.73%, respectively. The expression level of LncRNA H19 was related to K-L grading, and the expression level of LncRNA H19 increased with K-L grading. Pearson correlation analysis showed that LncRNA H19 was negatively correlated with bone metabolism indexes PINP, N-MID, BGP, BALP and Lysholm score (P<0.05), and positively correlated with bone metabolism indexes β-CTX, VAS score and WOMAC score (P<0.05).

Conclusion: LncRNA H19 is highly expressed in peripheral blood of patients with osteoarthritis, which is closely related to the occurrence and development of osteoarthritis and has a good diagnostic value for osteoarthritis.

1. Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan KP (2015). Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Oste-oarthritis Cartilage, 23: 507-515.
2. da Costa BR, Reichenbach S, Keller N, Nar-tey L, Wandel S, Jüni P, Trelle S (2017). Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet, 390: e21-e33.
3. Machado GC, Maher CG, Ferreira PH, et al(2015). Efficacy and safety of paraceta-mol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ, 350: h1225.
4. Qin J, Barbour KE, Murphy LB, et al (2017). Lifetime risk of symptomatic hand oste-oarthritis: the Johnston County Osteoar-thritis Project. Arthritis Rheumatol, 69: 1204-1212.
5. Machado GC, Maher CG, Ferreira PH, et al (2015). Efficacy and safety of paracetamol for spinal pain and osteoarthritis: system-atic review and meta-analysis of random-ised placebo controlled trials. BMJ, 350: h1225.
6. Tiulpin A, Thevenot J, Rahtu E, Lehenkari P, Saarakkala S (2018). Automatic knee osteoarthritis diagnosis from plain radio-graphs: A deep learning-based approach. Sci Rep, 8: 1727.
7. Nguyen LT, Sharma AR, Chakraborty C, Saibaba B, Ahh M-E, Lee SS (2017). Re-view of prospects of biological fluid bi-omarkers in osteoarthritis. Int J Mol Sci, 18: 601.
8. Kurth HM, Mochizuki K (2009). Non-coding RNA: a bridge between small RNA and DNA. RNA Biol, 6: 138-140.
9. Liu Q, Zhang X, Dai L, et al (2014). Long noncoding RNA related to cartilage injury promotes chondrocyte extracellular ma-trix degradation in osteoarthritis. Arthritis Rheumatol, 66: 969-978.
10. Steck E, Boeuf S, Gabler J, Werth N, Schnatzer P, Diederichs S, Richter W (2012). Regulation of H19 and its encod-ed microRNA-675 in osteoarthritis and under anabolic and catabolic in vitro conditions. J Mol Med (Berl), 90: 1185-1195.
11. He P, Zhang Z, Huang G, Wang H, Xu D, Liao W, Kang Y (2016). miR-141 modu-lates osteoblastic cell proliferation by reg-ulating the target gene of lncRNA H19 and lncRNA H19-derived miR-675. Am J Transl Res, 8: 1780.
12. Sinusas K (2012). Osteoarthritis: diagnosis and treatment. Am Fam Physician, 85.
13. Livshits G, Zhai G, Hart DJ, et al (2009). In-terleukin‐6 is a significant predictor of ra-diographic knee osteoarthritis: The Chingford study. Arthritis Rheum, 60: 2037-2045.
14. Mas Garriga X (2014). Definition, etiology, classification and presentation forms. Aten Primaria, 46: 3-10.
15. Brandt KD, Dieppe P, Radin EL (2008). Etiopathogenesis of osteoarthritis. Rheum Dis Clin North Am, 34: 531-559.
16. Jiang SD, Lu J, Deng ZH, Li YS, Lei GH (2017). Long noncoding RNAs in osteo-arthritis. Joint Bone Spine, 84: 553-556.
17. Khalil AM, Guttman M, Huarte M, et al (2009). Many human large intergenic noncoding RNAs associate with chroma-tin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A, 106: 11667-11672.
18. Pearson MJ, Jones SW (2016). Long noncoding RNAs in the regulation of in-flammatory pathways in rheumatoid ar-thritis and osteoarthritis. Arthritis Rheu-matol, 68: 2575.
19. Ding C, Garnero P, Cicuttini F, Scott F, Cooley H, Jones G (2005). Knee cartilage defects: association with early radiograph-ic osteoarthritis, decreased cartilage vol-ume, increased joint surface area and type II collagen breakdown. Osteoarthritis Carti-lage, 13: 198-205.
20. Xing D, Liang JQ, Li Y, et al (2014). Identification of long noncoding RNA associated with osteoar-thritis in humans. Orthop Surg 6: 288-293.
IssueVol 49 No 8 (2020) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v49i8.3893
Osteoarthritis Diagnosis Blood

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
ZHOU L, WAN Y, CHENG Q, SHI B, ZHANG L, CHEN S. The Expression and Diagnostic Value of LncRNA H19 in the Blood of Patients with Osteoarthritis. Iran J Public Health. 2020;49(8):1494-1501.